“Our data suggest SGLT2 inhibition as a safe strategy to prevent kidney stone recurrence in patients with kidney stones ,” Dr Fuster’s team concluded. Other study findings indicate the empagliflozin ...

GLP-1 receptor agonists were more cardioprotective in younger people, but reduced HbA1c more with age. The age of type 2 ...

“Our data suggest SGLT2 inhibition as a safe strategy to prevent kidney stone recurrence in patients with kidney stones,” Dr Fuster’s team concluded. Other study findings indicate the ...

Because SGLT2 inhibitors act on the kidney, and the amount of glucose excreted is closely dependent on the glomerular filtration rate (GFR), it can be anticipated that SGLT2 inhibitors will have a ...

Bayer has filed its mineralocorticoid receptor antagonist (MRA) finerenone as a treatment for a common form of heart failure ...

Renal glucose reabsorption involves two transporter families: the SGLTs secondary active Na + /D-glucose co-transporters located at the brush border of tubular cells (SGLT2 and SGLT1) and the ...

A combination of an SGLT-2 inhibitor drug and a moderately calorie-restrictive diet leads to higher rates of type 2 diabetes ...

The big core is focus on preservation of renal function in CKD, and I mentioned previously, SGLT2 inhibitors slow down progressive renal failure and actually raise hemoglobin. They seem to ...

The best treatment begins with just focusing on slowing down progressive renal failure, and that means using ACE inhibitors or ARBs combined with an SGLT2. If you're talking about stage three and ...

With respect to risks, GLP-1RA use was significantly associated with an increased risk of gastrointestinal disorders, hypotension, syncope, arthritic disorders, drug-induced pancreatitis, and other ...

Renal complications were reduced by 18% ... for cardiovascular events or CKD progression or are unable to use an SGLT2 therapy. In it favour also is that it does not work as a diabetes medicine ...

The global diabetic nephropathy market was valued at $1.9 billion in 2021, and is projected to reach $3.3 billion by 2031, growing at a CAGR of 6%.